Novo Nordisk: From Peak Performance To Needing A Booster Shot
I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...
As Lilly Stock Tumble on GLP-1 Demand Worries, CEO Says All Is Well
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
Lexaria Bioscience Corp.: Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval
Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria B ...
New Analysis Shows Successful Weight Maintenance After GLP-1 Discontinuation When Paired with Omada Health Behavior Change Program
Omada Health, the virtual between-visit healthcare provider, today announced new results of an analysis that aimed to better understand weight maintenance following GLP-1 medication discontinuation ...
The American Journal of Managed Care6d
Collaboration to Transition Members to Preferred Formulary Dipeptidyl-Peptidase-4 Inhibitor
A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor.
GLP-1 Medications Fuel Growth in Medical Aesthetics, with Weight Loss Accounting for 11% of Non-Surgical Spending in 2024
Guidepoint Qsight, a leader in leveraging proprietary data to provide unmatched analytics solutions, today revealed new ...